{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T03:20:04Z","timestamp":1788232804119,"version":"build-2803163510"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T00:00:00Z","timestamp":1781740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T00:00:00Z","timestamp":1787788800000},"content-version":"vor","delay-in-days":70,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Biol Eng"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Bispecific antibodies (bsAbs) have unlocked new therapeutic modalities by enabling dual antigen targeting, offering transformative potential in oncology and autoimmune diseases. However, the efficient production of full-length IgG-like bsAbs remains hindered by mispairing of heavy and light chains, yielding heterogeneous, low-purity products. Here, we present an Fc engineering strategy, termed StrandLock, that enables the controlled assembly of bsAbs through asymmetric \u03b2-strand redistribution at the CH3 dimer interface, in which the \u03b2-strand segment (residues N390\u2013S400) is duplicated in one heavy chain and deleted from the partner. This structural asymmetry, combined with targeted point mutations, promotes obligate heterodimerization while suppressing homodimer formation. Importantly, these modifications enable the correct assembly of bsAbs with purities approaching 99% and allow streamlined manufacturing via a single-step affinity purification process comparable to that used for monoclonal antibodies. The engineered bsAbs retain key Fc effector functions and exhibit comparable in vivo pharmacokinetics to native IgG. Structural analysis confirms preservation of the CH3 fold and native-like interfacial packing. Despite a modest reduction in thermal stability, the molecules remain aggregation-resistant and functionally robust under accelerated stress conditions. We further demonstrate the versatility of the StrandLock design across multiple antibody pairs underscoring its utility as a strategy for bsAb production.<\/jats:p>","DOI":"10.1186\/s13036-026-00717-x","type":"journal-article","created":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T06:15:46Z","timestamp":1781763346000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Engineering Fc heterodimerization via asymmetric \u03b2-strand reconfiguration for bispecific antibody assembly"],"prefix":"10.1186","volume":"20","author":[{"given":"Arkaitz","family":"Cano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Izaskun","family":"Morillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ainhoa","family":"Goenaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Elena","family":"Laugieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ander","family":"de Blas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eunate","family":"Valdaliso-D\u00edez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"June","family":"Ere\u00f1o-Orbea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz","family":"Apellaniz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4465-5071","authenticated-orcid":false,"given":"Edurne","family":"Rujas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,18]]},"reference":[{"key":"717_CR1","doi-asserted-by":"publisher","unstructured":"Brinkmann U, Kontermann RE. Bispecific antibodies. Science (80-) [Internet]. 2021;372:916\u20137. https:\/\/doi.org\/10.1126\/science.abg1209.","DOI":"10.1126\/science.abg1209"},{"key":"717_CR2","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1016\/j.ctrv.2015.10.008","volume":"41","author":"LM Henricks","year":"2015","unstructured":"Henricks LM, Schellens JHM, Huitema ADR, Beijnen JH. The use of combinations of monoclonal antibodies in clinical oncology. Cancer Treat Rev Neth. 2015;41:859\u201367. https:\/\/doi.org\/10.1016\/j.ctrv.2015.10.008.","journal-title":"Cancer Treat Rev Neth"},{"key":"717_CR3","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1038\/s41573-019-0028-1","volume":"18","author":"AF Labrijn","year":"2019","unstructured":"Labrijn AF, Janmaat ML, Reichert JM, Parren PWHI. Bispecific antibodies: a mechanistic review of the pipeline. Nat Rev Drug Discov Springer US. 2019;18:585\u2013608. https:\/\/doi.org\/10.1038\/s41573-019-0028-1.","journal-title":"Nat Rev Drug Discov Springer US"},{"key":"717_CR4","doi-asserted-by":"publisher","first-page":"4595","DOI":"10.4049\/JIMMUNOL.1403014","volume":"194","author":"M Pyzik","year":"2015","unstructured":"Pyzik M, Rath T, Lencer WI, Baker K, Blumberg RS. FcRn: The Architect Behind the Immune and Nonimmune Functions of IgG and Albumin. J Immunol Oxf Acad. 2015;194:4595\u2013603. https:\/\/doi.org\/10.4049\/JIMMUNOL.1403014.","journal-title":"J Immunol Oxf Acad"},{"key":"717_CR5","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1038\/nri2206","volume":"8","author":"F Nimmerjahn","year":"2008","unstructured":"Nimmerjahn F, Ravetch JV. Fc\u03b3 receptors as regulators of immune responses. Nat Rev Immunol [Internet]. 2008;8:34\u201347. https:\/\/doi.org\/10.1038\/nri2206.","journal-title":"Nat Rev Immunol [Internet]"},{"key":"717_CR6","doi-asserted-by":"publisher","unstructured":"Kontermann RE, Brinkmann U. Bispecific antibodies. Drug Discov Today [Internet]. 2015;20:838\u201347. https:\/\/doi.org\/https:\/\/doi.https:\/\/doi.org\/10.1016\/j.drudis.2015.02.008.","DOI":"10.1016\/j.drudis.2015.02.008"},{"key":"717_CR7","doi-asserted-by":"publisher","first-page":"8739","DOI":"10.1021\/bi9902079","volume":"38","author":"A W\u00f6rn","year":"1999","unstructured":"W\u00f6rn A, Pl\u00fcckthun A. Different equilibrium stability behavior of scFv fragments: Identification, classification, and improvement by protein engineering. Biochemistry. 1999;38:8739\u201350. https:\/\/doi.org\/10.1021\/bi9902079.","journal-title":"Biochemistry"},{"key":"717_CR8","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/B978-0-12-386483-3.00004-5","volume":"84","author":"D Lowe","year":"2011","unstructured":"Lowe D, Dudgeon K, Rouet R, Schofield P, Jermutus L, Christ D. Aggregation, stability, and formulation of human antibody therapeutics. Adv Protein Chem Struct Biol Neth. 2011;84:41\u201361. https:\/\/doi.org\/10.1016\/B978-0-12-386483-3.00004-5.","journal-title":"Adv Protein Chem Struct Biol Neth"},{"key":"717_CR9","first-page":"2098","volume":"95","author":"A L\u00f6ffler","year":"2000","unstructured":"L\u00f6ffler A, Kufer P, Lutterb\u00fcse R, Zettl F, Daniel PT, Schwenkenbecher JM, et al. A recombinant bispecific single-chain antibody, CD19 x CD3, induces rapid and high lymphoma-directed cytotoxicity by unstimulated T lymphocytes. Blood United States. 2000;95:2098\u2013103.","journal-title":"Blood United States"},{"key":"717_CR10","doi-asserted-by":"publisher","first-page":"5","DOI":"10.2147\/CPAA.S42689","volume":"5","author":"CA Portell","year":"2013","unstructured":"Portell CA, Wenzell CM, Advani AS. Clinical and pharmacologic aspects of blinatumomab in the treatment of B-cell acute lymphoblastic leukemia. Clin Pharmacol. 2013;5:5\u201311. https:\/\/doi.org\/10.2147\/CPAA.S42689.","journal-title":"Clin Pharmacol"},{"key":"717_CR11","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1158\/1078-0432.CCR-16-0666","volume":"23","author":"L Liu","year":"2017","unstructured":"Liu L, Lam C-YK, Long V, Widjaja L, Yang Y, Li H, et al. MGD011, A CD19 x CD3 Dual-Affinity Retargeting Bi-specific Molecule Incorporating Extended Circulating Half-life for the Treatment of B-Cell Malignancies. Clin cancer Res United States. 2017;23:1506\u201318. https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-0666.","journal-title":"Clin cancer Res United States"},{"key":"717_CR12","first-page":"2815","volume":"130","author":"G Lorenczewski","year":"2017","unstructured":"Lorenczewski G, Friedrich M, Kischel R, Dahlhoff C, Anlahr J, Bal\u00e1zs M, et al. Generation of a Half-Life Extended Anti-CD19 BiTE\u00aeAntibody Construct Compatible with Once-Weekly Dosing for Treatment of CD19-Positive Malignancies. Blood. 2017;130:2815.","journal-title":"Blood"},{"key":"717_CR13","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1158\/1535-7163.MCT-17-1086","volume":"17","author":"PA Moore","year":"2018","unstructured":"Moore PA, Shah K, Yang Y, Alderson R, Roberts P, Long V, et al. Development of MGD007, a gpA33 x CD3-Bispecific DART Protein for T-Cell Immunotherapy of Metastatic Colorectal Cancer. Mol Cancer Ther United States. 2018;17:1761\u201372. https:\/\/doi.org\/10.1158\/1535-7163.MCT-17-1086.","journal-title":"Mol Cancer Ther United States"},{"key":"717_CR14","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.nbt.2016.12.010","volume":"39","author":"S Krah","year":"2017","unstructured":"Krah S, Sellmann C, Rhiel L, Schr\u00f6ter C, Dickgiesser S, Beck J, et al. Engineering bispecific antibodies with defined chain pairing. N Biotechnol Neth. 2017;39:167\u201373. https:\/\/doi.org\/10.1016\/j.nbt.2016.12.010.","journal-title":"N Biotechnol Neth"},{"key":"717_CR15","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1093\/protein\/9.7.617","volume":"9","author":"JB Ridgway","year":"1996","unstructured":"Ridgway JB, Presta LG, Carter P. Knobs-into-holes engineering of antibody CH3 domains for heavy chain heterodimerization. Protein Eng Engl. 1996;9:617\u201321. https:\/\/doi.org\/10.1093\/protein\/9.7.617.","journal-title":"Protein Eng Engl"},{"key":"717_CR16","doi-asserted-by":"publisher","first-page":"19637","DOI":"10.1074\/jbc.M110.117382","volume":"285","author":"K Gunasekaran","year":"2010","unstructured":"Gunasekaran K, Pentony M, Shen M, Garrett L, Forte C, Woodward A, et al. Enhancing Antibody Fc Heterodimer Formation through Electrostatic Steering Effects: applications to bispecific molecules and monovalent IgG. J Biol Chem [Internet]. 2010;285:19637\u201346. https:\/\/doi.org\/10.1074\/jbc.M110.117382.","journal-title":"J Biol Chem [Internet]"},{"key":"717_CR17","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1093\/protein\/gzp094","volume":"23","author":"JH Davis","year":"2010","unstructured":"Davis JH, Aperlo C, Li Y, Kurosawa E, Lan Y, Lo K-M, et al. SEEDbodies: fusion proteins based on strand-exchange engineered domain (SEED) CH3 heterodimers in an Fc analogue platform for asymmetric binders or immunofusions and bispecific antibodies\u2020. Protein Eng Des Sel. 2010;23:195\u2013202. https:\/\/doi.org\/10.1093\/protein\/gzp094.","journal-title":"Protein Eng Des Sel"},{"key":"717_CR18","doi-asserted-by":"publisher","first-page":"9745","DOI":"10.1074\/jbc.M117.782433","volume":"292","author":"D Skegro","year":"2017","unstructured":"Skegro D, Stutz C, Ollier R, Svensson E, Wassmann P, Bourquin F, et al. Immunoglobulin domain interface exchange as a platform technology for the generation of Fc heterodimers and bispecific antibodies. J Biol Chem Elsevier. 2017;292:9745\u201359. https:\/\/doi.org\/10.1074\/jbc.M117.782433.","journal-title":"J Biol Chem Elsevier"},{"key":"717_CR19","doi-asserted-by":"publisher","first-page":"5145","DOI":"10.1073\/pnas.1220145110","volume":"110","author":"AF Labrijn","year":"2013","unstructured":"Labrijn AF, Meesters JI, de Goeij BECG, van den Bremer ETJ, Neijssen J, van Kampen MD, et al. Efficient generation of stable bispecific IgG1 by controlled Fab-arm exchange. Proc Natl Acad Sci [Internet]. 2013;110:5145\u201350. https:\/\/doi.org\/10.1073\/pnas.1220145110.","journal-title":"Proc Natl Acad Sci [Internet]"},{"key":"717_CR20","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1093\/protein\/gzx041","volume":"30","author":"A Kuglstatter","year":"2017","unstructured":"Kuglstatter A, Stihle M, Neumann C, M\u00fcller C, Schaefer W, Klein C, et al. Structural differences between glycosylated, disulfide-linked heterodimeric Knob-into-Hole Fc fragment and its homodimeric Knob-Knob and Hole-Hole side products. Protein Eng Des Sel Engl. 2017;30:649\u201356. https:\/\/doi.org\/10.1093\/protein\/gzx041.","journal-title":"Protein Eng Des Sel Engl"},{"key":"717_CR21","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1038\/nbt0798-677","volume":"16","author":"AM Merchant","year":"1998","unstructured":"Merchant AM, Zhu Z, Yuan JQ, Goddard A, Adams CW, Presta LG, et al. An efficient route to human bispecific IgG. Nat Biotechnol [Internet]. 1998;16:677\u201381. https:\/\/doi.org\/10.1038\/nbt0798-677.","journal-title":"Nat Biotechnol [Internet]"},{"key":"717_CR22","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1016\/S0022-2836(99)80014-X","volume":"216","author":"S Miller","year":"1990","unstructured":"Miller S. Protein-protein recognition and the association of immunoglobulin constant domains. J Mol Biol. 1990;216:965\u201373. https:\/\/doi.org\/10.1016\/S0022-2836(99)80014-X.","journal-title":"J Mol Biol"},{"key":"717_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/protein\/gzac012","volume":"35","author":"ND Pomarici","year":"2022","unstructured":"Pomarici ND, Fern\u00e1ndez-Quintero ML, Quoika PK, Waibl F, Bujotzek A, Georges G, et al. Bispecific antibodies - Effects of point mutations on CH3-CH3 interface stability. Protein Eng Des Sel. 2022;35:1\u201313. https:\/\/doi.org\/10.1093\/protein\/gzac012.","journal-title":"Protein Eng Des Sel"},{"key":"717_CR24","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1038\/s42003-025-09066-9","volume":"8","author":"I Morillo","year":"2025","unstructured":"Morillo I, Zulaica J, Caballero R, Auzmendi-Iriarte A, Largo J, Apellaniz E. Engineering a single-chain immunoglobulin scaffold loaded with a latent-releasable cytotoxic pore-forming peptide. Commun Biol [Internet]. 2025;8:1665. https:\/\/doi.org\/10.1038\/s42003-025-09066-9.","journal-title":"Commun Biol [Internet]"},{"key":"717_CR25","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1016\/S1097-2765(01)00230-1","volume":"7","author":"WL Martin","year":"2001","unstructured":"Martin WL, West AP, Gan L, Bjorkman PJ. Crystal structure at 2.8 \u00c5 of an FcRn\/heterodimeric Fc complex: Mechanism of pH-dependent binding. Mol Cell. 2001;7:867\u201377. https:\/\/doi.org\/10.1016\/S1097-2765(01)00230-1.","journal-title":"Mol Cell"},{"key":"717_CR26","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/0161-5890(96)00004-1","volume":"33","author":"S Popov","year":"1996","unstructured":"Popov S, Hubbard JG, Kim JK, Ober B, Ghetie V, Ward ES. The stoichiometry and affinity of the interaction of murine Fc fragments with the MHC class I-related receptor, FcRn. Mol Immunol. 1996;33:521\u201330. https:\/\/doi.org\/10.1016\/0161-5890(96)00004-1.","journal-title":"Mol Immunol"},{"key":"717_CR27","doi-asserted-by":"publisher","first-page":"646","DOI":"10.4161\/mabs.25632","volume":"5","author":"TS Von Kreudenstein","year":"2013","unstructured":"Von Kreudenstein TS, Escobar-Carbrera E, Lario PI, D\u2019Angelo I, Brault K, Kelly J, et al. Improving biophysical properties of a bispecific antibody scaffold to aid developability: quality by molecular design. MAbs. 2013;5:646\u201354. https:\/\/doi.org\/10.4161\/mabs.25632.","journal-title":"MAbs"},{"key":"717_CR28","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1126\/science.abb8008","volume":"369","author":"A Kumar","year":"2020","unstructured":"Kumar A, Planchais C, Fronzes R, Mouquet H, Reyes N. Binding mechanisms of therapeutic antibodies to human CD20. Sci United States. 2020;369:793\u20139. https:\/\/doi.org\/10.1126\/science.abb8008.","journal-title":"Sci United States"},{"key":"717_CR29","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1208\/s12248-024-01003-8","volume":"27","author":"Z Hu","year":"2025","unstructured":"Hu Z, Wu P, Swanson SJ. Evaluating the Immunogenicity Risk of Protein Therapeutics by Augmenting T Cell Epitope Prediction with Clinical Factors. AAPS J [Internet]. 2025;27:33. https:\/\/doi.org\/10.1208\/s12248-024-01003-8.","journal-title":"AAPS J [Internet]"},{"key":"717_CR30","doi-asserted-by":"publisher","first-page":"3363","DOI":"10.4049\/jimmunol.160.7.3363","volume":"160","author":"S Southwood","year":"1998","unstructured":"Southwood S, Sidney J, Kondo A, del Guercio M-F, Appella E, Hoffman S, et al. Several Common HLA-DR Types Share Largely Overlapping Peptide Binding Repertoires. J Immunol [Internet]. 1998;160:3363\u201373. https:\/\/doi.org\/10.4049\/jimmunol.160.7.3363.","journal-title":"J Immunol [Internet]"},{"key":"717_CR31","doi-asserted-by":"publisher","first-page":"e0178544","DOI":"10.1371\/journal.pone.0178544","volume":"12","author":"HS Schultz","year":"2017","unstructured":"Schultz HS, Reedtz-Runge SL, B\u00e4ckstr\u00f6m BT, Lamberth K, Pedersen CR, Kvarnhammar AM. Quantitative analysis of the CD4\u2009+\u2009T cell response to therapeutic antibodies in healthy donors using a novel T cell:PBMC assay. PLoS One United States. 2017;12:e0178544. https:\/\/doi.org\/10.1371\/journal.pone.0178544.","journal-title":"PLoS One United States"},{"key":"717_CR32","doi-asserted-by":"publisher","first-page":"e0159328","DOI":"10.1371\/journal.pone.0159328","volume":"11","author":"MK Joubert","year":"2016","unstructured":"Joubert MK, Deshpande M, Yang J, Reynolds H, Bryson C, Fogg M, et al. Use of In Vitro Assays to Assess Immunogenicity Risk of Antibody-Based Biotherapeutics. PLoS One United States. 2016;11:e0159328. https:\/\/doi.org\/10.1371\/journal.pone.0159328.","journal-title":"PLoS One United States"},{"key":"717_CR33","doi-asserted-by":"publisher","first-page":"11187","DOI":"10.1073\/pnas.1019002108","volume":"108","author":"W Schaefer","year":"2011","unstructured":"Schaefer W, Regula JT, B\u00e4hner M, Schanzer J, Croasdale R, D\u00fcrr H, et al. Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies. Proc Natl Acad Sci [Internet]. 2011;108:11187\u201392. https:\/\/doi.org\/10.1073\/pnas.1019002108.","journal-title":"Proc Natl Acad Sci [Internet]"},{"key":"717_CR34","doi-asserted-by":"crossref","unstructured":"Lu RM, Hwang YC, Liu IJ, Lee CC, Tsai HZ, Li HJ et al. Development of therapeutic antibodies for the treatment of diseases. J Biomed Sci. 2020;27.","DOI":"10.1186\/s12929-019-0592-z"},{"key":"717_CR35","doi-asserted-by":"publisher","first-page":"520","DOI":"10.3389\/fimmu.2014.00520","volume":"5","author":"G Vidarsson","year":"2014","unstructured":"Vidarsson G, Dekkers G, Rispens T. IgG Subclasses and Allotypes: From Structure to Effector Functions. Front Immunol [Internet]. 2014;5:520. https:\/\/doi.org\/10.3389\/fimmu.2014.00520.","journal-title":"Front Immunol [Internet]"},{"key":"717_CR36","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1038\/nbt0102-87","volume":"20","author":"T Nagai","year":"2002","unstructured":"Nagai T, Ibata K, Park ES, Kubota M, Mikoshiba K, Miyawaki A. A variant of yellow fluorescent protein with fast and efficient maturation for cell-biological applications. Nat Biotechnol. 2002;20:87\u201390. https:\/\/doi.org\/10.1038\/nbt0102-87.","journal-title":"Nat Biotechnol"},{"key":"717_CR37","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1107\/S0907444909047337","volume":"66","author":"W Kabsch","year":"2010","unstructured":"Kabsch W, BA T, D K, KP A, D K. S M et al XDS Acta Crystallogr Sect D Biol Crystallogr [Internet]. 2010;66:125\u201332. http:\/\/scripts.iucr.org\/cgi-bin\/paper?S0907444909047337.","journal-title":"S M et al XDS Acta Crystallogr Sect D Biol Crystallogr [Internet]"},{"key":"717_CR38","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1107\/S0021889807021206","volume":"40","author":"AJ McCoy","year":"2007","unstructured":"McCoy AJ, Grosse-Kunstleve RW, Adams PD, Winn MD, Storoni LC, Read RJ. Phaser crystallographic software. J Appl Crystallogr. 2007;40:658\u201374. https:\/\/doi.org\/10.1107\/S0021889807021206.","journal-title":"J Appl Crystallogr"},{"key":"717_CR39","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1107\/S0907444910007493","volume":"66","author":"P Emsley","year":"2010","unstructured":"Emsley P, Lohkamp B, Scott WG, Cowtan K. Features and development of Coot. Acta Crystallogr Sect D Biol Crystallogr. 2010;66:486\u2013501. https:\/\/doi.org\/10.1107\/S0907444910007493.","journal-title":"Acta Crystallogr Sect D Biol Crystallogr"},{"key":"717_CR40","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1107\/S0907444909052925","volume":"66","author":"PD Adams","year":"2010","unstructured":"Adams PD, Afonine PV, Bunk\u00f3czi G, Chen VB, Davis IW, Echols N, et al. PHENIX: A comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr Sect D Biol Crystallogr. 2010;66:213\u201321. https:\/\/doi.org\/10.1107\/S0907444909052925.","journal-title":"Acta Crystallogr Sect D Biol Crystallogr"}],"container-title":["Journal of Biological Engineering"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13036-026-00717-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13036-026-00717-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13036-026-00717-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T01:06:18Z","timestamp":1787792778000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13036-026-00717-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,18]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["717"],"URL":"https:\/\/doi.org\/10.1186\/s13036-026-00717-x","relation":{},"ISSN":["1754-1611"],"issn-type":[{"value":"1754-1611","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,18]]},"assertion":[{"value":"12 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Samples and data from donors included in the immunogenicity assessment were provided by the Basque Biobank (\n                      \n                      ) and were processed following standard operation procedures with appropriate approval of the Ethical and Scientific Committees (code CEIC E19-75). All participants provided written informed consent, and the study was conducted in accordance with the Declaration of Helsinki. All experimental procedures involving SCID mice were conducted in accordance with European Union regulations on animal experimentation and were approved by the Ethics Committee on Animal Research (CEEA) of the Research and Development Center (CID-CSIC) under protocol OH-1696\/2024.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"132"}}